A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Due to business reasons, enrollment on the study was halted and the study terminated. The decision to close enrollment was not due to any safety concern.

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Entinostat
DRUG: Erlotinib

Sponsor

Syndax Pharmaceuticals